Highlights Abstract Background: Increasing obesity and metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis present challenges in liver...
Read More
By Eugenia Tsai, MD A recent Nature Communications study by Kalsotra and colleagues offers new molecular insight into...
For Melroy Koehler, transplant morning arrived with a surprise: his own bubble parade. He...
The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting...
Key Takeaways The phase 2 study of a bemnifosbuvir and ruzasvir regimen for the...
Fabian Rodas Ochoa, MD, transplant hepatologist and clinical assistant professor of medicine at UT...
Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis,...